ReviewActa ortopedica brasileira2025
ROLE OF POLYMORPHISMS IN VEGF AND KDR GENES IN OSTEOSARCOMA SUSCEPTIBILITY: A SYSTEMATIC REVIEW.
Review in Acta ortopedica brasileira, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma is the most common aggressive primary bone tumor in children and adolescents. Angiogenesis, induced by vascular endothelial growth factor (VEGF) and its receptor (kinase insert domain receptor - KDR) is involved in tumor development. Both genes (VEGF and KDR) are polymorphic, and their association with osteosarcoma remains unclear. A systematic review of observational studies was performed to evaluate the association between polymorphisms in these genes and osteosarcoma development. Pubmed, Medline, Lilacs, and Scielo databases were searched for observational studies published up to April 2024. Eight publications of case-control studies were included, with quality ranging from 82% to 95%. All subjects were from the Chinese population: 1,681 cases and 2,049 controls. A total of six VEGF polymorphisms were analyzed. For osteosarcoma susceptibility, three studies found an increased risk with VEGF rs699947, four with VEGF rs2010963, two with VEGF rs3025039, one with VEGF rs833061, and no studies found an association with the VEGF rs1570360 and VEGF rs10434 SNPs. In addition, no studies evaluated SNPs in the KDR gene and osteosarcoma susceptibility. Further studies in diverse populations, particularly in Brazil, are necessary to clarify the role of VEGF and KDR polymorphisms in osteosarcoma development and prognosis. Level of evidence III; Systematic Review.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.